A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
Recruiting · NCT06930794 · Registry updated 2026-05-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-05-01 | NCT06930794 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Pearl Biotechnology Limited Liability Company | 5 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing | China | 71 |
| Guangdong Provincial People's Hospital | Guangzhou | China | 85 |